company background image
524824 logo

Bal Pharma BSE:524824 Stock Report

Last Price


Market Cap







15 Jun, 2024


Company Financials

524824 Stock Overview

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta.

524824 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance5/6
Financial Health3/6

Bal Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bal Pharma
Historical stock prices
Current Share Price₹118.45
52 Week High₹132.20
52 Week Low₹80.60
1 Month Change17.94%
3 Month Change25.21%
1 Year Change34.27%
3 Year Change21.99%
5 Year Change111.52%
Change since IPO1,072.77%

Recent News & Updates

Recent updates

Shareholder Returns

524824IN PharmaceuticalsIN Market

Return vs Industry: 524824 underperformed the Indian Pharmaceuticals industry which returned 53.9% over the past year.

Return vs Market: 524824 underperformed the Indian Market which returned 44.9% over the past year.

Price Volatility

Is 524824's price volatile compared to industry and market?
524824 volatility
524824 Average Weekly Movement8.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.5%
10% most volatile stocks in IN Market9.5%
10% least volatile stocks in IN Market4.3%

Stable Share Price: 524824 has not had significant price volatility in the past 3 months.

Volatility Over Time: 524824's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company


Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India, Uzbekistan, Guatemala, and Malta. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands.

Bal Pharma Limited Fundamentals Summary

How do Bal Pharma's earnings and revenue compare to its market cap?
524824 fundamental statistics
Market cap₹1.86b
Earnings (TTM)₹73.92m
Revenue (TTM)₹3.39b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524824 income statement (TTM)
Cost of Revenue₹1.92b
Gross Profit₹1.47b
Other Expenses₹1.40b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date


Earnings per share (EPS)4.71
Gross Margin43.47%
Net Profit Margin2.18%
Debt/Equity Ratio201.6%

How did 524824 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.